FDA sparks AVEO investors' hopes for tivozanib in RCC
This article was originally published in Scrip
Executive Summary
A correspondence from the FDA to AVEO raised investors' hopes there may potentially be a way forward for the company's tyrosine kinase inhibitor tivozanib in renal cell carcinoma (RCC) – a path once considered dead and buried – triggering shares of the company to soar 28.3% on 20 May.